1-6 of 6
Thomas Brunner
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT186: HEPANOVA: Interim safety analysis from a phase 2 study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with sorafenib in advanced hepatocellular carcinoma (HCC)

Eleni Gkika, Thomas Brunner, Robert Thimme, Anca-Ligia Grosu
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT186.
https://doi.org/10.1158/1538-7445.AM2020-CT186
Published: 15 August 2020
View article titled, Abstract CT186: HEPANOVA: Interim safety analysis from a phase 2 study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with sorafenib in advanced hepatocellular carcinoma (HCC)
Journal Articles

Abstract CT175: HEPANOVA Phase II study design for advanced hepatocellular carcinoma: Tumor treating fields concomitant with sorafenib

Anca-Ligia Grosu, Eleni Gkika, Thomas Brunner, Robert Thimme, Uri Weinberg
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT175.
https://doi.org/10.1158/1538-7445.AM2019-CT175
Published: 01 July 2019
View article titled, Abstract CT175: HEPANOVA Phase II study design for advanced hepatocellular carcinoma: Tumor treating fields concomitant with sorafenib
Journal Articles

Abstract CT084: HEPANOVA: A phase II trial of tumor treating fields concomitant with sorafenib for advanced hepatocellular carcinoma

Anca-Ligia Grosu, Josif Strouthos, Thomas Brunner, Uri Weinberg
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): CT084.
https://doi.org/10.1158/1538-7445.AM2018-CT084
Published: 01 July 2018
View article titled, Abstract CT084: HEPANOVA: A phase II trial of tumor treating fields concomitant with sorafenib for advanced hepatocellular carcinoma
Journal Articles

Abstract 5501: Evaluation of the first potent and highly selective inhibitor of ATR kinase: An approach to selectively sensitize cancer cells to ionizing radiation and hypoxia

Gillies McKenna, Thomas Brunner, Peter Charlton, Emmanouil Fokas, Ester Hammond, Matthew Mangan, Monica Olcina, Isabel Pires, John Pollard, Remko Prevo, Philip Reaper
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 5501.
https://doi.org/10.1158/1538-7445.AM2011-5501
Published: 15 April 2011
View article titled, Abstract 5501: Evaluation of the first potent and highly selective inhibitor of ATR kinase: An approach to selectively sensitize cancer cells to ionizing radiation and hypoxia
Journal Articles

miR-15a and miR-16 Are Implicated in Cell Cycle Regulation in a Rb-Dependent Manner and Are Frequently Deleted or Down-regulated in Non–Small Cell Lung Cancer

Nora Bandi, Samuel Zbinden, Mathias Gugger, Marlene Arnold, Verena Kocher, Lara Hasan, Andreas Kappeler, Thomas Brunner, Erik Vassella
Journal: Cancer Research
Cancer Res (2009) 69 (13): 5553–5559.
https://doi.org/10.1158/0008-5472.CAN-08-4277
Published: 01 July 2009
View article titled, <em>miR-15a</em> and <em>miR-16</em> Are Implicated in Cell Cycle Regulation in a Rb-Dependent Manner and Are Frequently Deleted or Down-regulated in Non–Small Cell Lung Cancer
Open the PDF for <em>miR-15a</em> and <em>miR-16</em> Are Implicated in Cell Cycle Regulation in a Rb-Dependent Manner and Are Frequently Deleted or Down-regulated in Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Human Lung Carcinomas Express Fas Ligand

Gloria A. Niehans, Thomas Brunner, Sandra P. Frizelle, Jacob C. Liston, Christopher T. Salerno, Dennis J. Knapp, Douglas R. Green, Robert A. Kratzke
Journal: Cancer Research
Cancer Res (1997) 57 (6): 1007–1012.
Published: 01 March 1997
View article titled, Human Lung Carcinomas Express Fas Ligand
Open the PDF for Human Lung Carcinomas Express Fas Ligand in another window